MEI Pharma Inc
NASDAQ:MEIP
MEI Pharma Inc
Revenue
MEI Pharma Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
MEI Pharma Inc
NASDAQ:MEIP
|
Revenue
$72.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
83%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is MEI Pharma Inc's Revenue?
Revenue
72.7m
USD
Based on the financial report for Dec 31, 2023, MEI Pharma Inc's Revenue amounts to 72.7m USD.
What is MEI Pharma Inc's Revenue growth rate?
Revenue CAGR 5Y
83%
Over the last year, the Revenue growth was 16%. The average annual Revenue growth rates for MEI Pharma Inc have been 17% over the past three years , 83% over the past five years .